BioSpace News Archive

Biosynthetic Technologies, a leader in environmentally sustainable base oils, today announced the appointment of Dr. Matthew Kriech as its new Chief Executive Officer, effective immediately.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced 2023 year-end Annamycin clinical trials preliminary data and 2024 expectations for multiple data readouts and a transition to pivotal Phase 2B/3 clinical studies.

Lexaria Bioscience Corp. is pleased to provide this annual letter from CEO Chris Bunka as a strategic update to all stakeholders.

Cadrenal Therapeutics, Inc. announced today that Douglas Losordo , M.D., Chief Medical Officer of Cadrenal, will participate in a fireside chat moderated by Joe Pantginis, Ph.D., Managing Director of Research at H.C. Wainwright & Co., at the Lytham Partners 2024 Investor Select Conference.

Motif Neurotech announced today an oversubscribed Series A financing of $18.75 million led by Arboretum Ventures.

From reducing toxins in personal-care products to granting more people access to clean water, UL Research Institutes is helping to build the future of safety science with funding opportunities open to applicants worldwide.

We are pleased to provide an update on our recent milestones and strategic decisions shaping Sirona Biochem’s path forward.

icotec ag is pleased to announce a significant milestone in its growth journey by establishing a strategic partnership with MVM Partners, a global healthcare venture capital firm.

Verisense Health combined its wearable technology expertise and clinical research knowledge to satisfy this unmet market need.

In a significant advancement for cancer research and treatment, Astrin Biosciences, a leader in AI-empowered 3D holographic technology for cancer cell detection, has announced a comprehensive research collaboration with Memorial Sloan Kettering Cancer Center.